Jazz Pharmaceuticals plc (JAZZ) financials — revenue, cash, debt and margins

Jazz Pharmaceuticals plc (JAZZ) financials — revenue, cash, debt and margins — InspectStocks

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $15.1B
P/E (TTM): 15.89
Price / sales: 3.28
EV / EBITDA: 11.76
Price / book: 3.14

Cash flow

FCF yield: 10.5%
SBC-adjusted FCF yield: 8.5%
SBC impact: 19.3%
Stock compensation (TTM): $306.7M

Margins & growth

Profit margin: 20.4%
Operating margin: 19.5%
Quarterly revenue (year on year): 15.5%
Quarterly earnings (year on year): —

Balance sheet

Cash & investments: $452.6M
Debt: $4.4B
Net cash / (debt): -$3.9B

Where the revenue comes from

Xywav is 39% of revenue.

By product or service

Year to Dec 31, 2025 · $4.3B

Xywav39%
$1.7B+12.5% vs. a year earlier
Epidiolex Epidyolex25%
$1.1B+8.9% vs. a year earlier
Rylaze Enrylaze9%
$402.9M-1.9% vs. a year earlier
Zepzelca7%
$307.3M-4.1% vs. a year earlier
High Sodium AG Oxybate Product Royalty Revenue5%
$211.7M-2.7% vs. a year earlier
Defitelio Defibrotide5%
$199.4M-7.9% vs. a year earlier
Vyxeos3%
$146.7M-9.8% vs. a year earlier
Xyrem3%
$146M-37.5% vs. a year earlier
Modeyso1%
$48M
Other Royalties and Contract Revenue1%
$34M+12.6% vs. a year earlier
Ziihera1%
$24.8M+2,260.6% vs. a year earlier
Sativex0.38%
$16.3M-13.8% vs. a year earlier
Other Products0.33%
$14.2M+23.5% vs. a year earlier

By region

Year to Dec 31, 2025 · $4.3B

United States90%
$3.8B+4.7% vs. a year earlier
Europe8%
$341.1M+9.1% vs. a year earlier
Other Countries2%
$94.9M-1.3% vs. a year earlier

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Total Revenue

$4.6BQ2 2026+3.7%

1Y: +12.59%2Y: +17.68%5Y: +75.23%

Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.

EBITDA

$1.61BQ2 2026+139.2%

1Y: +323.69%2Y: +33.60%5Y: +95.59%

Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit

$940.76MQ2 2026+3,093.0%20.4% of revenue

1Y: +332.38%2Y: +138.21%5Y: +2,242.30%

What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit margin

20.4%Q2 2026+2,980.2%

How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.

Free Cash Flow

$1.59BQ2 2026+25.3%

1Y: +25.79%2Y: +52.32%5Y: +111.04%

Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit per share

$14.63Q2 2026+13,200.0%

1Y: +314.52%2Y: +150.94%5Y: +1,440.00%

The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.

Shares outstanding

64.54MQ2 2026+3.3%

How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.

Price to earnings

14.5xQ2 2025+1.7%

14.5x today · median 19.2x and range 10.5x–60.5x across the points shown, Q1 2018 to Q2 2025 The break in the line covers 10 periods with no meaningful multiple — a loss, or earnings so small the ratio says more about the denominator than the price.

Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.

About Jazz Pharmaceuticals plc

Ticker: JAZZ
SEC classification: Pharmaceutical Preparations (2834)
Listed on: Nasdaq
Incorporated in: L2
Financial year ends: December 31
Filer size: Large accelerated filer

About this data

Everything above comes from Jazz Pharmaceuticals plc’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Not reported by this filer: Cost of Revenue, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Total Liabilities, Short-term Borrowings, Borrowings (total), and Dividends paid. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $15.1B
P/E (TTM): 15.89
Price / sales: 3.28
EV / EBITDA: 11.76
Price / book: 3.14

Cash flow

FCF yield: 10.5%
SBC-adjusted FCF yield: 8.5%
SBC impact: 19.3%
Stock compensation (TTM): $306.7M

Margins & growth

Profit margin: 20.4%
Operating margin: 19.5%
Quarterly revenue (year on year): 15.5%
Quarterly earnings (year on year): —

Balance sheet

Cash & investments: $452.6M
Debt: $4.4B
Net cash / (debt): -$3.9B

Where the revenue comes from

Xywav is 39% of revenue.

By product or service

Year to Dec 31, 2025 · $4.3B

Xywav39%
$1.7B+12.5% vs. a year earlier
Epidiolex Epidyolex25%
$1.1B+8.9% vs. a year earlier
Rylaze Enrylaze9%
$402.9M-1.9% vs. a year earlier
Zepzelca7%
$307.3M-4.1% vs. a year earlier
High Sodium AG Oxybate Product Royalty Revenue5%
$211.7M-2.7% vs. a year earlier
Defitelio Defibrotide5%
$199.4M-7.9% vs. a year earlier
Vyxeos3%
$146.7M-9.8% vs. a year earlier
Xyrem3%
$146M-37.5% vs. a year earlier
Modeyso1%
$48M
Other Royalties and Contract Revenue1%
$34M+12.6% vs. a year earlier
Ziihera1%
$24.8M+2,260.6% vs. a year earlier
Sativex0.38%
$16.3M-13.8% vs. a year earlier
Other Products0.33%
$14.2M+23.5% vs. a year earlier

By region

Year to Dec 31, 2025 · $4.3B

United States90%
$3.8B+4.7% vs. a year earlier
Europe8%
$341.1M+9.1% vs. a year earlier
Other Countries2%
$94.9M-1.3% vs. a year earlier

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Total Revenue

$4.6BQ2 2026+3.7%

1Y: +12.59%2Y: +17.68%5Y: +75.23%

Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.

EBITDA

$1.61BQ2 2026+139.2%

1Y: +323.69%2Y: +33.60%5Y: +95.59%

Profit

$940.76MQ2 2026+3,093.0%20.4% of revenue

1Y: +332.38%2Y: +138.21%5Y: +2,242.30%

What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit margin

20.4%Q2 2026+2,980.2%

Free Cash Flow

$1.59BQ2 2026+25.3%

1Y: +25.79%2Y: +52.32%5Y: +111.04%

Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit per share

$14.63Q2 2026+13,200.0%

1Y: +314.52%2Y: +150.94%5Y: +1,440.00%

Shares outstanding

64.54MQ2 2026+3.3%

Price to earnings

14.5xQ2 2025+1.7%

About Jazz Pharmaceuticals plc

Ticker: JAZZ
SEC classification: Pharmaceutical Preparations (2834)
Listed on: Nasdaq
Incorporated in: L2
Financial year ends: December 31
Filer size: Large accelerated filer

About this data

Everything above comes from Jazz Pharmaceuticals plc’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.